top of page
  • Writer's pictureAmit Kukreja

BREAKING: A Palantir Consortium of Competitors Throw In The Towel

In a recent development reported by Digital Health, the UK consortium vying for the opportunity to manage the National Health Service's (NHS) £480 million Federated Data Platform (FDP) has been unsuccessful, according to Shane Tickell, CEO and founder of consortium member Voror Health Technologies. The consortium, which includes database firm Eclipse and software provider Black Pear, had hoped to rival US data analytics titan Palantir for the lucrative contract.

The FDP, a data analytics platform designed to track population health, care coordination, elective recovery, vaccines, and supply chains, is seen as a future "operating system for the health service," according to NHS England officials. They envision the platform as a central hub to provide managers and senior civil servants with valuable insights for decision-making.

However, the consortium's failure to secure the contract has positioned Palantir as the frontrunner, despite ongoing concerns from privacy and legal advocacy groups. Critics argue that Palantir's connections to US intelligence and security services make it an unpalatable choice for handling sensitive personal health data. If you have been keeping up with this story, you know that Palantir was likely going to win this contract from the beginning. It was only a matter of time until the NHS realized what we all knew: one company can get the job done better than hundreds because that one company actually knows what they are doing.

The NHS has experience significant backlog reductions in different hospitals and extreme efficiencies in vaccine distributions because of Palantir. It was just hard to imagine any level of incompetency strong enough to justify not giving Palantir this contract.

The company's experience in handling large-scale data projects, as well as their ability to facilitate collaboration and integration between various data sources, could be game-changing for the NHS. Here are five ways Palantir could help:

  1. Enhanced data-driven decision-making: Palantir's sophisticated data analysis tools could enable the NHS to make more informed decisions by providing real-time insights into various aspects of healthcare, including patient outcomes, resource allocation, and the effectiveness of medical interventions. This data-driven approach could lead to improved patient care and help in identifying opportunities for cost savings and increased efficiency.

  2. Improved care coordination and resource allocation: Palantir's platform can integrate disparate data sources, offering a unified view of patient records and healthcare services. This would facilitate better care coordination among healthcare providers, reducing the chances of medical errors and improving the overall patient experience. Additionally, the platform could help optimize resource allocation by identifying areas of high demand or undersupply and informing strategic decisions on staffing, funding, and equipment.

  3. Faster identification of health trends and risks: By collecting and analyzing data from various sources, Palantir's platform could help the NHS identify emerging health trends and potential risks more quickly. This would enable healthcare providers to develop targeted interventions, implement preventative measures, and allocate resources more effectively in response to changing healthcare needs.

  4. Strengthened disease surveillance and outbreak management: Palantir has already demonstrated its capabilities in managing pandemic-related data during the Covid-19 crisis. If awarded the FDP contract, the company could help the NHS more effectively monitor and respond to infectious disease outbreaks by streamlining data collection and analysis from multiple sources, enabling faster decision-making and more effective public health interventions.

  5. Boosted innovation and research: Palantir's platform could provide researchers and healthcare professionals with unprecedented access to comprehensive, anonymized health data. This data trove would facilitate new discoveries, improve the understanding of complex health issues, and accelerate the development of new treatments and therapies. Moreover, the platform's ability to easily collaborate with research institutions and industry partners could foster a more innovative and efficient healthcare ecosystem.

None of the above-mentioned benefits could be implemented at scale and in a way that actually works without Palantir, and it seems like most legacy IT companies have thrown in the towel because they see the writing on the wall.

As the saga continues, stakeholders will be closely monitoring the contract outcome and its implications for the future of data management within the NHS.

Thanks for reading the article. If you'd like to get in contact, please @ me on twitter here or email me at You can join our Palantir Facebook group here to participate in community discussions, polls, and more. You can check out daily palantir audio content here.